Cargando…

Renin-angiotensin system inhibitors in hospitalised patients with COVID-19

Detalles Bibliográficos
Autor principal:	Williams, Bryan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836517/ https://www.ncbi.nlm.nih.gov/pubmed/33422264 http://dx.doi.org/10.1016/S2213-2600(21)00003-5

Ejemplares similares

Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19
por: Williams, Bryan, et al.
Publicado: (2020)

Renin–angiotensin system inhibitors and COVID-19: overwhelming evidence against an association
por: de Abajo, Francisco J
Publicado: (2021)

Renin-angiotensin-aldosterone system inhibitors and the COVID-19 epidemic
por: Silva-Cardoso, José, et al.
Publicado: (2022)

Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic
por: South, Andrew M., et al.
Publicado: (2020)

Renin–angiotensin system inhibition in COVID-19 patients: Friend or foe?
por: Karadağ, Bilgehan
Publicado: (2020)

Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19
por: Furuhashi, Masato, et al.
Publicado: (2020)

Should we continue to use renin–angiotensin–aldosterone system blockers in patients with COVID-19?
por: Copur, Sidar, et al.
Publicado: (2022)

Renin Angiotensin System Inhibition as treatment for Covid-19?
por: Williams, Professor Bryan
Publicado: (2021)

Monoclonals for patients hospitalised with COVID-19
por: Pogue, Jason M, et al.
Publicado: (2022)

Renin–angiotensin system inhibitors and mortality in patients with COVID-19
por: Rossi, Luca, et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
por: Vaduganathan, Muthiah, et al.
Publicado: (2020)

Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19
por: Jarcho, John A., et al.
Publicado: (2020)

Renin–angiotensin–aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis
por: Ssentongo, Anna E, et al.
Publicado: (2020)

Convalescent plasma in patients hospitalised with COVID-19
por: Liu, Sean T H, et al.
Publicado: (2021)

Antiviral monotherapy for hospitalised patients with COVID-19 is not enough
por: Cao, Bin, et al.
Publicado: (2020)

Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties
por: Matthay, Michael A, et al.
Publicado: (2020)

Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts
por: Mahajan, Kunal, et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
por: Reynolds, Harmony R., et al.
Publicado: (2020)

Impact of renin–angiotensin–aldosterone system inhibitors on COVID-19
por: Matsuzawa, Yasushi, et al.
Publicado: (2022)

Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
por: Benenson, Irina, et al.
Publicado: (2020)

Early oral antiviral use in patients hospitalised with COVID-19
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

COVID-19 and the Renin-Angiotensin System
por: Malha, Line, et al.
Publicado: (2020)

COVID-19 and involuntary hospitalisation: navigating the challenge
por: Gold, Azgad, et al.
Publicado: (2020)

Alternatives to conventional hospitalisation that enhance health systems' capacity to treat COVID-19
por: Nicolás, David, et al.
Publicado: (2021)

Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update
por: Shukla, Ashwin Kumar, et al.
Publicado: (2021)

Effect of renin-angiotensin-aldosterone system inhibitors on Covid-19 patients in Korea
por: Park, Jungchan, et al.
Publicado: (2021)

The systemic renin-angiotensin system in COVID-19
por: Reindl-Schwaighofer, Roman, et al.
Publicado: (2022)

Is there enough evidence to discontinue the renin-angiotensin system inhibitors in patients with COVID-19?
por: Bobkova, Irina, et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients
por: Trifirò, Gianluca, et al.
Publicado: (2020)

Hospitalisation among vaccine breakthrough COVID-19 infections
por: Juthani, Prerak V, et al.
Publicado: (2021)

Baricitinib as the treatment of choice for hospitalised individuals with COVID-19
por: Richardson, Peter J., et al.
Publicado: (2022)

Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review
por: Ferrari, Filipe, et al.
Publicado: (2021)

Renin‐Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID‐19
por: Loader, Jordan, et al.
Publicado: (2021)

Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Hypothesis for renin-angiotensin inhibitor mitigation of COVID-19
por: Sackin, Henry
Publicado: (2021)

Renin–Angiotensin–Aldosterone Inhibitors and COVID-19 Infection
por: Tsampasian, Vasiliki, et al.
Publicado: (2022)

Commentary to Angiotensin-Converting-Enzyme 2 and Renin–Angiotensin System Inhibitors in COVID-19: An Update
por: Ferri, Claudio, et al.
Publicado: (2021)

Renin-angiotensin system inhibition in COVID-19 patients
por: de Vries, A. A. F.
Publicado: (2020)

Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19
por: Shapiro, Adrienne E, et al.
Publicado: (2022)

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19
por: So-Osman, Cynthia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9fsbm0av0tl2tnkjkkpk3jebq2